Preetesh Jain

47PUBLICATIONS
175CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|Jul 02, 2026
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance.

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Aug 05, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.

Zachary D Epstein-Peterson, Anath C Lionel, Ashlee Joseph

|Jul 23, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.

Wei Wang, Qingsong Cai, Yang Liu

|Jan 09, 2025
High-risk MCL: recognition and treatment.

Preetesh Jain, Michael Wang

Pageof 8

Frequent Collaborators

19 joint publications

Michael Wang

8 joint publications

Chi Young Ok

8 joint publications

Rashmi Kanagal-Shamanna

5 joint publications

Yucai Wang